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Abstract: Belimumab is the first biologic approved for patients with systemic lupus 
  erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating 
factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-
activating factor from the tumor necrosis factor family), is a type II transmembrane protein 
that exists in both membrane-bound and soluble forms. Additionally to a robust rational from 
murine experiments conducted in lupus prone mice, BLyS circulating levels are increased in 
SLE patients. After the negative results of a Phase II trial, two Phase III trials met their primary 
endpoints. Some SLE patients are still refractory to the standard options of care or necessitate 
prolonged high-dose corticotherapy and/or long-term immunosuppressive regimens. However, 
some experts still feel that the effect of this biologic might not be clinically relevant and blame 
the use of the new systemic lupus response index as well as the discrepancies between both 
trials and the noninclusion of the severe form of the disease as nephritis. In this review, we 
aim to discuss the characteristics of belimumab, critically evaluate the different steps of its 
development, and consider its future place in the arsenal against SLE, taking into account the 
patients’ perspectives.
Keywords: systemic lupus erythematosus, belimumab, treatment, monoclonal antibodies, 
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Introduction
Although biologics have largely revolutionized the management of patients with 
  rheumatoid arthritis (RA) during the past decade,1 belimumab, the first biologic for 
patients with systemic lupus erythematosus (SLE), developed by Human Genome 
  Sciences Inc, (HGS, Rockville, MD) in collaboration with GlaxoSmithKline 
(Research Triangle Park, NC), was only approved in 2011 by the US Food and Drug 
  Administration (FDA) and the European Medicines Agency (EMA).2,3
For many reasons, this approval was considered an important milestone for SLE, 
but also, more broadly, in the field of systemic autoimmune diseases. Firstly, this 
is the first approval for .50 years by the FDA of a drug for this indication, which 
explains the hopes raised among patients and physicians who had become accustomed 
to using mostly off-label drugs (Table 1). Secondly, belimumab is the first biologic to 
be directly derived from genomics to reach the market. It is the result of the “proof 
of principle” that has translated the data generated by the Human Genome Project 
into clinical practice.4 Thirdly, belimumab is also the first drug to have a successful 
B cell-targeting strategy. It may rebalance the failure to obtain significant results in 
recent prospective trials using other B-cell depletive approaches,5,6 and could pave 
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the way towards developing new targeted agents for this 
disease (Table 2).
However, many clinicians in the field do not share 
this enthusiasm,7,8 and their pessimistic comments on this 
recently labeled drug may antagonize other physicians and 
patients. Indeed, from a scientific point of view, the most 
surprising aspect is probably that some physicians persist 
in supporting rituximab for SLE, although it has failed to 
Table 1 Drugs used to treat lupus with or without label
Drugs FDA EMA AFSSAPS
Prednisone  NA 
Prednisolone  NA 
Methylprednisolone  NA 
Aspirine  NA –
NSAIDs – NA –
Chloroquine – NA 
Hydroxychloroquine  NA 
Thalidomide – – §
Azathioprine – NA 
Cyclophosphamide – NA 
Methotrexate – NA –
Mycophenomate mofetil – – –
Cyclosporine – NA –
Rituximab – – §
Belimumab * ** NA
Notes:  ,  approval;  –,  no  approval;  NA,  no  evaluation  available;  §,  special 
authorizations: thalidomide for severe cutaneous lupus, rituximab for severe SLE 
refractory to immunosuppressants and/or plasmapheresis (“Protocole  Thérapeutique 
Temporaire”).  *Seropositive  patients,  with  SLE  refactory  to  standard  regimen; 
**seropositive patients, with SLE refractory to standard regimen and positive anti-
DNA antibodies and low complement levels.
Abbreviations: FDA, Food and Drug Administration; EMA, European Medicines 
Agency; AFFSAPS, Agence Française de Sécurité Sanitaire des Produits de Santé.
Table 2 Drugs targeting BLyS pathway under development for SLE
Company Product/route  
of administration
Target Status and ongoing or planned trials  
(www.clinicaltrials.gov)
Evaluation
Human Genome  
Sciences Inc/ 
GlaxoSmithKline
Benlysta belimumab  
LymphoStat-B  
intravenous
Human mAb targeting  
soluble BLyS (BAFF)
Approved by FDA and EMA 
NCT00724867 NCT00712933  
NCT00583362 Phase III (long-term safety) 
NCT01345253 PhIII (Asia) 
NCT00732940 Phase II (Subcutaneous)
SRI
Eli Lilly LY2127399 
Subcutaneous
Human mAb targeting  
soluble and membrane- 
bound BLyS (BAFF)
NCT01196091 NCT01205438 Phase III SRI
Merck KGaA/ 
Bristol-Myers Squibb
Atacicept (TACI-Ig) 
Subcutaneous
BLyS and APRIL  
(Soluble fusion protein  
containing the extracellular  
portion of TACI linked to Fc)
NCT00573157 Phase II/III* 
NCT00624338 Phase II/III 
NCT01440231 Phase II (dose response*)
Renal response 
BILAG 
SRI-50
Anthera  
Pharmaceuticals Inc/ 
Amgen
A-623 AMG 623  
Blisibimod 
Subcutaneous
Peptide fusion protein that  
antagonizes soluble and  
membrane-bound BLyS (BAFF)
NCT01395745 Phase II 
NCT01162681 Phase II 
NCT01305746 Phase II (safety)
SRI 
SLE response**
Notes: *Dose of 5 to 115 mg/weekly because 150 mg dose judged unfavorable in renal Phase II/III trials; **SLE response is defined as the percentage of subjects with SLE 
response compared with baseline at the time of assessment (SRI included in secondary endpoints).
Abbreviations: BILAG, British Isles Lupus Assessment Group; SLE, systemic lupus erythematosus; SRI, SLE Response Index.
meet its primary endpoints in two prospective Phase III 
trials.5,6 This is in contrast to belimumab, which has provided 
positive results in two prospective Phase III trials that have 
included about 1700 SLE patients9,10 and have followed FDA 
recommendations.11
In this review, we discuss the characteristics of belimumab, 
critically evaluate the different steps in its development, and 
assess its future place in the arsenal against SLE.
Management issues for lupus
SLE is a chronic autoimmune disease involving multiple 
organs with a large diversity of possible clinical mani-
festations, including, among others, arthritis, pleuritis, 
  pericarditis, stroke, seizure, nephritis, anemia, thrombocy-
topenia, photosensitivity, and rash.12 The disease primarily 
affects women of child-bearing age, and has a prevalence 
of up to 1.5 million in the USA alone.12 SLE evolution is 
characterized by inflammatory flare-ups that can ultimately 
cause permanent damage to multiple organ systems, which 
explains why it has one of the highest mortality rates among 
autoimmune diseases.12,13
Current treatment options to relieve symptoms and 
control the progression of SLE include antimalarial drugs 
(mainly hydroxychloroquine), steroidal and nonsteroidal 
anti-inflammatory agents, nonspecific immunosuppressive 
drugs, including methotrexate, azathioprine, cyclophosph-
amide, cyclosporine, mycophenolate mofetil (MMF), and 
biologics. However, only a few of these drugs have been 
approved (Table 1), hydroxychloroquine being the last drug 
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to be labeled by the FDA for SLE in the 1950s. In many 
countries, a “graduated” therapeutic escalation has been 
recommended.14 Standard options of care (SOC) for mild 
to moderate SLE consist of nonsteroidal anti-inflammatory 
drugs (NSAIDs), antimalarials, and corticosteroids, while 
life-threatening flare-ups, such as those affecting the kidneys 
or central nervous system (CNS), are treated with high-dose 
corticosteroids, and immunosuppressive agents such as 
cyclophosphamide and azathioprine, or MMF. Importantly, 
recent immunological and clinical research strongly supports 
the broad use of antimalarials for all SLE patients (includ-
ing patients receiving immunosuppressants) to help prevent 
complications.13,15,16
In spite of this arsenal, some patients are still refractory 
to SOC or need prolonged high-dose corticotherapy and/or a 
long-term immunosuppressive regimen to maintain   remission. 
In many cases, the drugs themselves cause   irreversible dam-
age, sometimes leading to death. Among other serious side 
effects, corticosteroids cause weight gain, hypertension, 
increased susceptibility to infection,   osteoporosis, while 
immunosuppressants increase the risk of infections   (including 
opportunist pathogens), malignancy, and   infertility. Actually, 
avoiding this “collateral” damage is the strongest ratio-
nale for the development of biologics. Unfortunately for 
SLE patients, so far, available biologics have been either not 
recommended, such as tumor necrosis factor (TNF) block-
ers that can induce SLE17, or have not gained approval in 
prospective evaluations, such as rituximab.5,6 In this context, 
belimumab has just been labeled, but its place in the manage-
ment of SLE is already a matter of debate, as evidenced, for 
example, by the discrepancies between the labeling given by 
the FDA and EMA (Table 1).
Pharmacology, mode of action, and 
pharmacokinetics of belimumab
To most immunologists, the physiopathology of SLE is so 
complex that the identification of a single factor/molecule 
that can mirror TNF-α for RA seemed until recently nearly 
  impossible.18 Nevertheless, the rationale for developing 
B-  lymphocyte (BLy) inhibitors has been robust and has included 
successive in vitro, murine, and human investigations.
SLE is a systemic autoimmune disease characterized by 
autoantibody production against self-antigens (Ags). B-cell 
stimulatory factors that can promote the loss of B-cell toler-
ance and drive autoantibody production are exciting new 
candidates. In 1997, HGS discovered and rapidly identified 
the function of the B-lymphocyte stimulator (BLyS) protein.19 
BLyS, also known as BAFF (B-cell-activating factor from 
the TNF family), is a type II transmembrane protein that 
exists in both membrane-bound and soluble forms.19 BLyS 
is expressed at the surface of a wide variety of immune cell 
types (monocytes, activated neutrophils, T cells, and dendritic 
cells), and its expression/secretion can be increased by vari-
ous inflammatory cytokines.20,21
When cleaved from the membrane, BLyS becomes a 
soluble trimer that is a ligand for three receptors expressed 
primarily on B lymphocytes (Figure 1): BLyS receptor 3 
(BR3 or BAFF-R), transmembrane activator-1, calcium 
modulator and cyclophilin ligand-interactor (TACI), and 
B-B-lymphocyte stimulator cell maturation antigen (BCMA). 
BLyS is the sole ligand for BR3, whereas TACI and BCMA 
can each bind with BLyS or another TNF family ligand 
known as a proliferation-inducing ligand (APRIL). These 
ligand–receptor interactions vary in affinity and BLyS binds 
more strongly to BR3 than to TACI or BCMA. In theory, 
APRIL can mediate effects similar to those of BLyS, but 
as the three BLyS family receptors vary in their expression 
patterns and levels across different B-cell subsets, its bio-
logic action may be primarily on memory and plasma cells 
(Figure 1). In vitro, BLyS exhibits a strong costimulatory 
function on B-cell activation that leads to B-cell and plasma 
cell proliferation, differentiation, and survival, and to immu-
noglobulin G (IgG) class switching.19
Interestingly, results from murine models have indicated 
that increased expression of BLyS may lead to systemic auto-
immune disease in mouse models and constitutes one of the 
first clues for a potential role for BLyS in human autoimmune 
disease. First, BLyS-transgenic mice developed severe B-cell 
hyperplasia and autoimmune lupus-like disease, character-
ized by the presence of autoantibodies against nuclear Ags 
and immune complex deposits in the kidneys.22,23 Secondly, 
in two murine models of human SLE (MRL/Mp-lpr/lpr and 
NZB/W F1 mice), there were increased serum levels of BLyS 
that correlated with autoimmune kidney damage, and treat-
ment with soluble BLyS receptors significantly improved 
survival of these lupus mice.24
In SLE patients, two cross-sectional studies have shown 
that serum levels of BLyS were significantly increased in a 
third of patients,25,26 and were associated with IgG levels and 
antidouble-stranded DNA (anti-dsDNA) titers. Of note, this 
increase was not specific to SLE, as high circulating BLyS 
levels were also observed in patients with RA, Sjögren, and 
antineutrophil cytoplasmic antibodies (ANCA)-associated 
vasculitis.27–29 Although patients with positive antinuclear 
antibodies (ANA), but no other American College of 
  Rheumatology (ACR) criteria for lupus, had marginally 
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elevated BLyS levels, those with positive ANA and several 
criteria for lupus had higher levels. However, in these studies, 
BLyS levels were not correlated with SLE activity when eval-
uated with the SLE Disease Activity Index (SLEDAI).25,26
To explain this lack of correlation, let us keep in 
mind that some pieces of the BLyS puzzle remain unan-
swered in humans (Figure 1). First, a 60-mer form of 
soluble BLyS (BLyS-60) has been observed in mice30 
and in vitro evidence suggests that BLyS-60 binds to 
TACI with 100-fold greater affinity than the canonical 
trimeric BLyS.31 However, the existence of a soluble 
BLyS-60 remains to be determined in humans. Secondly, 
BLyS–APRIL heterotrimers have also been character-
ized, but their function in vivo is unclear.32 Third, BLyS 
can be expressed as a membrane-bound protein by 
immune and also nonhematopoietic cells (osteoclasts 
and synovial fibroblasts).33 Finally, some have recently 
emphasized the contribution of BCMA in the production 
of autoantibodies,34 while others have reported an inverse 
correlation between APRIL and both BLyS levels and 
disease activity in SLE patients, suggesting a protective 
role for APRIL.35 In addition, a trial that tested atacicept 
(Figure 1) in another autoimmune condition, multiple 
sclerosis, was recently stopped because of an unexpected 
pro-inflammatory effect:36 this illustrates the limitations 
in our comprehension of this complex pathway.
The interpretation of BLyS levels is difficult in some 
specific settings. On the one hand, some have suggested that 
glomerulonephritis may increase BLyS excretion in the urine, 
thereby resulting in paradoxically lower plasma BLyS levels 
in patients with very active disease.37 On the other hand, the 
influence of certain drugs on BlyS/B-cell biology are also 
probably underestimated: as an example, rituximab-induced 
B-cell depletion is followed by an increase in BLyS level, 
which then returns to near-baseline levels when B cells are 
repopulated in ANCA vasculitis, RA, and SLE patients.38,39 
Finally, in a longitudinal study, using multivariate analysis 
with complex adjustments, Petri et al found that the level 
of BLyS at one patient’s visit was positively correlated 
with the increase in SELENA–SLEDAI (SS) score at the 
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Figure 1 BLyS, its receptors and “anti-BLyS” biologics. (A) BLyS exists in both membrane-bound form (at the surface of a wide variety of cell types as monocytes, activated 
neutrophils, T cells, and dendritic cells) and, after cleavage, soluble form, that is a ligand for three receptors on B lymphocytes: BLyS receptor 3 (BR3), transmembrane 
activator-1 and calcium modulator and cyclophilin ligand–interactor (TACI), and B cell maturation antigen (BCMA). BLyS is the sole ligand for BR3, whereas TACI and BCMA 
each can bind either BLyS or another ligand known as a proliferation-inducing ligand (APRIL). Belimumab blocks only soluble BLyS, whereas atacicept also blocks APRIL and 
other drugs (see Table 2*) also aim at membrane-bound BLyS. (B) The three BLyS family receptors vary in their expression patterns and levels across different B cell subsets, 
explaining why belimumab has little biologic action on memory and plasma cells.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36
Chiche et alTherapeutics and Clinical Risk Management 2012:8
  following visit,37 thus providing the missing link between in 
vitro/murine and human data.
Belimumab (Benlysta®; HGS) is a fully human IgG1λ 
recombinant monoclonal antibody directed against BLyS. 
Specific binding of belimumab with soluble BLyS prevents 
its interaction with its three receptors and indirectly decreases 
B-cell survival and production of autoantibodies.40 Although 
TACI and BCMA also bind to APRIL, BLyS is BR3’s only 
ligand and the interaction of BLyS and BR3 is necessary for 
survival of naïve B cells and mature primary B cells. This 
enables belimumab to have a greater effect on early B cells, 
such as naïve B cells, and a lesser effect on memory and 
plasma B cells (Figure 1).
Belimumab is the first of a new class of drugs to tar-
get B-cell stimulating factors or their receptors (Table 2). 
Importantly, in contrast to other drugs under development 
(Table 2), belimumab does not neutralize membrane-bound 
BLyS (Figure 1). Belimumab is administered intrave-
nously from single-use vials containing 120 or 400 mg of 
  lyophilized powder that is reconstituted to obtain 10 mg/kg 
of belimumab administered over 1 hour. The first three 
doses are administered every 2 weeks and then treatment is 
repeated every 4 weeks. A Phase I dose-ranging randomized 
controlled trial on 70 SLE patients demonstrated in vivo 
safety and provided pharmacokinetic data.40 The half-life of 
belimumab is 19–20 days, its volume of distribution is small 
(69–112 mL/kg), and clearance is slow (7 mL/day/kg). No 
significant pharmacokinetic change is seen with concomitant 
use of belimumab and NSAIDs, antimalarials, corticoster-
oids, methotrexate, azathioprine, or MMF; however, there are 
no available data concerning previous or ongoing administra-
tion of other biologics such as rituximab.
Efficacy studies, including  
any comparative studies
The following logical step in the development of   belimumab 
was to conduct a Phase II double-blind randomized 
  controlled trial on 449 SLE patients assigned to either 
  belimumab (1, 4, or 10 mg/kg) or a placebo, adminis-
tered intravenously on days 0, 14, and 28, and then every 
28 days for 52 weeks.41 All subjects also received the 
SOC, with a stable regimen of steroids, antimalarials, or 
  immunosuppressants for 60 days prior to the first belimumab 
dose.   Unfortunately, there were no significant differences 
between the treated and placebo groups regarding efficacy 
endpoints (  percentage of change in the SS score at 24 weeks 
and the time to first SLE flare-up), and no dose response 
was observed in this trial. However, some   secondary 
results were considered   interesting. First, the time until a 
first flare-up was longer with belimumab (154 days in the 
combined belimumab group compared to 104 days with the 
placebo, P = 0.036). This suggests that the drug could have 
a postponed effect, which is not visible at 24 weeks: indeed, 
a significant decrease in the mean physician’s global assess-
ment (PGA) score at 52 weeks was noted (31% with beli-
mumab compared to 14% with the placebo, P = 0.0019).
Secondly, post-hoc analysis of the subgroup of patients 
with serologically active disease (ANA .1:80 and/or anti-
dsDNA .30 IU/mL) yielded significantly better responses at 
52 weeks in belimumab- versus placebo-treated patients by 
SS score and PGA. This subset of patients exhibited higher 
disease activity (especially with regards to biologic markers) 
at baseline compared to ANA-negative patients. Finally, the 
large and poorly controlled use of corticosteroids was identi-
fied as a potential cause for the negative results in Phase II 
studies. In addition, in two later negative Phase II/III studies 
that tested rituximab in SLE patients, corticosteroids were 
blamed for masking the effect of the biologic therapy.5,6 All 
these points have led to major modifications in the design of 
Phase III trials for belimumab.
The most important measures were the restriction of 
inclusion to seropositive patients, and the introduction of a 
novel tool to assess changes in disease activity, which was 
used as the primary endpoint: the Systemic Lupus Erythe-
matosus Responder Index (SRI). In this compound index, SS 
scores were utilized to define global improvement, British 
Isles Lupus Assessment Group (BILAG) domain scores to 
ensure no significant worsening in previously unaffected 
systems, and PGA to ensure that improvement in disease 
activity was not achieved to the detriment of the patient’s 
overall condition. From reanalysis of Phase II data, the SRI 
was defined as a $4 point reduction in SS score compared 
to baseline, plus no worsening (increase ,0.3 points from 
baseline) in PGA score, plus absence of any new BILAG 
organ domain score of A or two new BILAG scores of B 
at week 52 compared to baseline. BILAG scores A and B, 
respectively, indicated a severe and moderate flare-up in any 
of the eight organ domains of the index.42
Two multicenter Phase III trials, BLISS-52 and BLISS-76, 
have been simultaneously conducted. In both trials, seropositive 
patients were randomized to one of three treatment groups: 
10 mg/kg belimumab, 1 mg/kg belimumab, or a placebo. 
SOC therapy was given to all enrolled patients in addition to 
respective treatment. Intravenous belimumab was administered 
on days 0, 14, and 28, then every 28 days thereafter for the 
duration of the study. In the BLISS-52 trial,9 which enrolled 
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865   seropositive patients, SRI rates were observed to be 
significantly higher in the belimumab-1 and 10-mg/kg group 
than with the placebo group at the end of week 52 (Table 3), 
whereas no significant difference was found between beli-
mumab and the placebo with respect to adverse effects. In the 
BLISS76 trial,10 819 seropositive patients were observed for 
76 weeks. The patients’ response rates, to be measured by SRI 
at weeks 52 and 76, were the primary and major secondary 
endpoints, respectively. No significant SRI improvement was 
seen with belimumab at 1 mg/kg compared to the placebo. 
However, the improvement was significantly higher in the 
10-mg/kg belimumab group than the placebo by week 52, but 
could not be sustained later and the difference by week 76 was 
not statistically significant (Table 3). The results of these two 
  studies, compatible with the June 2010 FDA guidelines,11 led to 
approval of belimumab in March 2011,2 but deserve additional 
comments to explain the skepticism of some reports.7,8
First, some have criticized the use of a novel (and automati-
cally poorly validated) composite endpoint to evaluate disease 
activity that was designed by HGS, namely SRI. The goal of 
devising a composite endpoint was to ensure that belimumab 
did not improve some manifestations at the expense of others. 
Whereas SS captures only the presence or absence of symptoms 
at a given point in time, BILAG captures improvement or wors-
ening within eight organ systems. However, although the BILAG 
was the preferred index for measuring disease reduction,11 the 
FDA had previously approved the choice of SRI. Nevertheless, 
it is important to note that choosing particular combinations 
of these parameters is not negligible. The different sensitivity 
of SS and BILAG might possibly provide totally different 
results with the same combination of parameters when used in 
a different way. This has been recently reported in an ongoing 
trial that compared SRI and BILAG-based Combined 
Lupus Assessment.43
The FDA and other experts have been concerned that 
only part of the scale was being used due to the exclusion 
of severe renal and CNS disease, and that a 4-point differ-
ence in scores might not be clinically meaningful using a 
reduced scale, especially as an ACR committee had concluded 
that a decrease of 7 points in SS was clinically meaningful.44 
Table 3 Efficacy results of belimumab in BLISS-52 and BLISS-76 Phase III trials
BLISS-52 (study C1057) BLISS-76 (study C1056)
Placebo  
(n = 287)
Benlysta  
1 mg/kg  
(n = 288)
Benlysta  
10 mg/kg  
(n = 290)
Placebo  
(n = 275)
Benlysta  
1 mg/kg  
(n = 271)
Benlysta  
10 mg/kg  
(n = 273)
Primary endpoint
SRI 125 (44%) 148 (51%) 167 (58%) 93 (34%) 110 (41%) 118 (43%)
Difference vs placebo 8% 14% 7% 9%
OR [95% CI] vs placebo 1.55 [1.10, 2.19] 1.83 [1.3, 2.59] 1.34 [0.94, 1.91] 1.52 [1.07, 2.15]
P-value 0.0129 0.0006 0.1041 0.0207
Subcomponents
  4-point reduction in 132 (46%) 153 (53%) 169 (58%) 98 (36%) 116 (43%) 128 (47%)
  OR [95% CI] vs placebo 1.51 [1.07, 2.14] 1.71 [1.21, 2.41] 1.36 [0.96, 1.93] 1.63 [1.15, 2.32]
  P-value 0.0189 0.0024 0.0869 0.0062
  No worsening in PGA 199 (69%) 227 (79%) 231 (80%) 173 (63%) 197 (73%) 189 (69%)
  OR [95% CI] vs placebo 1.68 [1.15, 2.47] 1.74 [1.18, 2.55] 1.60 [1.11, 2.30] 1.32 [0.92, 1.90]
  P-value 0.0078 0.0048 0.012 0.1258
  No new BILAG 210 (73%) 226 (79%) 236 (81%) 179 (65%) 203 (75%) 189 (69%)
  OR [95% CI] vs placebo 1.38 [0.93, 2.04] 1.62 [1.09, 2.42] 1.63 [1.12, 2.37] 1.20 [0.84, 1.73]
  P-value 0.1064 0.0181 0.0108 0.3193
Secondary endpoints on efficacy
SLE Flares over 52 w
    Median Time to first  
SELENA-SLEDAI Flare (days)
84 126 119 82 85 84
  OR [95% CI] vs placebo* 0.75 [0.62–0.90] 0.76 [0.63–0.91] 0.89 [0.74–1.08] 0.93 [0.78–1.13]
 P -value 0.0026 0.0036 0.2324 0.4796
SRI w76 – – – 89 (32%) 106 (39%) 105 (39%)
  Difference vs placebo – – 7% 6%
  OR [95% CI] vs placebo – – 1.3 [0.9–1.9] 1.3 [0.9–1.9]
  P-value – – 0.10 0.13
Note: *Median time to first flare was not available in the original paper,10 and corresponding hazard ratios were taken from the FDA official document.2
Abbreviations: BILAG, British Isles Lupus Assessment Group; CI, confidence interval; OR, Odds Ratio; PGA, physician’s global assessment; SRI, SLE Response Index; W, week.
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But post hoc sensitivity analyses showed that patients   receiving 
belimumab had a significantly greater rate of SRI response 
when higher SS thresholds of 5, 6, and 7 were used.45
In addition, although the designs of the two Phase III 
  trials were identical (except that patients in the BLISS-52 trial 
were treated for 48 weeks, and those in BLISS-76   continued 
treatment until 72 weeks), discrepancies exist between their 
results, which may be explained in part by some of the dif-
ference in the selected patients (Table 4), which leads to 
questions about the generalizability of these results. As an 
example, the less favorable results in the BLISS-76 trial 
could suggest decreased efficacy of belimumab in patients 
with late established SLE, as the mean disease duration of 
enrolled patients was longer in the BLISS-76 trial, and BLISS 
52 included almost no black patients, who have been shown 
to be unresponsive to belimumab in these studies.
Also, the management of other therapies was of 
  concern. No new immunosuppressants were permitted 
after randomization, and no increases in dose of immu-
nosuppressants or antimalarials was allowed after week 
16. Increases of steroids were limited after week 24. 
Thus, because these trials evaluated efficacy at 52 weeks 
(instead of the 24-week evaluation period in the Phase II 
trial), this seemed to evaluate the capacity of belimumab 
to maintain the response obtained after initial changes in 
SOC. Also, patients who required changes to background 
medications that were not permitted by the protocol were 
scored as treatment failures, which happened more often in 
the placebo group, and might have exaggerated the effect 
of belimumab. However, this point was also addressed by 
further sensitivity analyses.2
Finally, the clinical relevance of this new therapy has 
been questioned. The trials enrolled a total of 1684 patients 
who were positive for autoantibodies and had SS scores $6. 
The most commonly involved organ systems were musculo-
skeletal (60%), mucocutaneous (59%), hematologic (16%), 
renal (11%), general (11%), and vasculitis (9%): there were 
no data from patients who had involvement of organ systems 
associated with mortality (CNS or proliferative nephritis). 
Even if mucocutaneous and musculoskeletal symptoms are 
debilitating and reduce quality of life (Qol), they are not 
generally lethal. This questions the relevance of the effect 
of belimumab, which seemed overall to be mild: this was 
either because there was little effect in the whole population 
or only a significant effect in a subset of patients. The latter 
hypothesis seems probable. First, the effect did not seem to 
concern specific subsets, as black patients given belimumab 
did even worse than those given a placebo in the Phase III 
trials. Black patients, who account for about 25% of lupus 
patients in the USA, tend to have more severe disease than 
the general lupus population. Of note, the BLISS-52 trial 
included no patients from the USA and had only 4% of 
patients with an African heritage, whereas the BLISS-76 
trail had 14% black patients, though still far from the 25% 
expected in the USA. Thus, the negative results in the BLISS- 
76 trial at week 76 seem to be attributable to a lack of power 
due to exclusions, which implies that the huge sample size 
was probably one of the key factors to reach significance. In 
addition, required post-hoc analyses have been conducted 
and led EMA to restrict the label approved for belimumab 
to patients who are biologically active (positive anti-DNA 
and low complement levels), which is in contrast to the FDA 
recommendation.2,3
The mild and unsustained effect of belimumab, as well 
as the inability to clearly define which patients may benefit 
from belimumab, enables us to focus on the safety issues of 
Table 4   Difference  in  patients’  characteristics  between  the 
belimumab Phase III trials
Phase 3 trials BLISS-52  
(C1057)
BLISS-76  
(C1056)
Disease duration  
(year), mean
5.3 7.5
BILAG 1A/2B, % 58 64
SELENA-SLEDAI 9.8 9.7
Renal, % 20 11
Musculoskeletal, % 59 73
Cutaneous, % 82 82
Immunology, % 85 74
ANA positive, % 95 92
Anti-DNA positive, % 75 64
Low C4, % 59 53
SLICC/ACR damage  
index
0.57 0.99
Antimalarials, % 67 63
Corticosteroids, % 96 76
Prednisone .7.5 mg/day, % 69 46
Immunosuppressant, % 42 56
Geographic regions, % Latin America 50 
Asia 38 
Eastern Europe 11 
Australia 2
USA/Canada 53 
western Europe/
Israel 25 
Eastern Europe 11 
Latin America 11
Ethnicity, %
  Caucasian 27 70
  Asian 38 3
  Black/African American 4 14
    Alaskan Native/ 
American Indian
32 13
Abbreviations: ANA, antinuclear antibodies; BILAG, British Isles Lupus Assessment 
Group;  C4,  complement  fraction  C4;  SLICC,  Systemic  Lupus  International 
Collaborative Clinics/American College of Rheumatology Damage Index.
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this new drug and to evaluate its benefit/risk ratio, especially 
as this drug is intended for patients with no life-threatening 
form of SLE.
Safety and tolerability
As with any other newly approved molecule, the long-term 
safety of the drug needs to be monitored since the results 
of any trial cannot fully predict a drug’s safety profile in 
real-life practice (Table 2). Apart from the limited follow 
up of the three prospective trials, we also have data from 
open follow-up periods of .5 years.46,47 Besides infusion 
reactions, such as urticaria, and hematologic reactions, such 
as neutropenia and thrombocytopenia, which have been 
reported in some patients, few serious adverse events have 
been reported during the clinical trials. However, serious 
infections and suicides, due to severe depression, have been 
reported more frequently with belimumab than with placebo 
(0.8% vs 0.4%). Six malignancies occurred (one in a placebo 
patient, three on 1 mg/kg, and two on 10 mg/kg). More deaths 
were reported with belimumab at 1 and 10 mg/kg than with 
a placebo (0.7% and 0.9% vs 0.4%). There were four deaths 
related to infection (one in the placebo group, three in the 
belimumab groups), and infection may have contributed to 
two more deaths in the belimumab arms.
To know whether belimumab’s marginal efficacy is 
strong enough to justify individually the potential risks 
suggested by the small increases in a few serious adverse 
effects found in these trials, FDA calculated the death rate 
per 100 patient-years in the belimumab groups to be almost 
double that in the placebo group (0.79 vs 0.43; 95% confi-
dence intervals [CI]: 0.49–10.08). According to statistical 
experts, 11 patients needed to be treated to achieve one SRI 
response, based on the BLISS-76 trial, and seven needed to 
be treated based on the BLISS-52 trial, whereas, in pooled 
analysis of both trials, 342 was the number needed to harm, 
or the number who would need to be treated before one death 
occurred. Thus, one death should be expected for every 30 
or 50 patients who achieve an effect as the primary endpoint. 
However, against this pessimistic evaluation, the benefit/
ratio of initiating belimumab treatment should obviously 
not solely take into account the risk due to this biologic, 
but instead include the risk in the calculation if patients 
that do not receive belimumab remain dependent on other 
treatments, especially long-term corticosteroids and their 
morbidity–mortality and impact on QoL. Of course, these 
safety concerns require a strict long-term follow-up, espe-
cially to detect rare side effects or side effects that may be   
more prevalent in patients outside of trials, who often exhibit 
more comorbidities.
Patient-focused perspectives such as 
QoL, patient satisfaction/acceptability, 
adherence, and uptake
From a patient’s perspective, the efficacy of a drug is not 
the only important issue. Unfortunately, results from the 
secondary endpoints generally did not support the primary 
analysis. Week 76 response rate, a secondary endpoint in 
BLISS-76, was not significant (Table 3). Numerically, more 
patients in the belimumab arms in both trials were able to 
reduce their steroid use by $25% to #7.5 mg/day, a sec-
ondary endpoint. But the results were inconsistent for the 
other steroid-related secondary endpoint.2,3 Especially, in 
the BLISS-76 trial, fewer patients given 1 mg/kg belimumab 
needed to increase their steroid dose compared to the placebo 
group, but the 10-mg/kg arm needed similar steroid doses 
to the placebo group.2 Also, patients with a severe form of 
SLE, a seronegative form, or black SLE patients were not 
concerned by the presented results, as attested by the label 
attributed by the FDA and the nonbiologically active SLE 
patients outlined by EMA.2,3
Finally, from careful examination of the data available 
so far, it is clear that the decision to approve belimumab 
was probably influenced by the lack of hope in this field, 
an influence that is practically impossible to avoid in severe 
diseases. This was recently illustrated by the withdrawal of 
accelerated approval for bevacizumab (Avastin; Genentech/
Roche, South San Francisco, CA) for metastatic breast cancer 
by the FDA:48 we fully agree that physicians and researchers 
have the obligation to “give hope – but not false hope”. To 
paraphrase the recent words of Dr Sekeres,48 and of course 
setting aside the issue of the cost of belimumab, what kind 
of conversation would I have with such a patient if I were 
trying to convince her to take a treatment like belimumab? 
“Well, I can offer you a drug that will not make you live lon-
ger (belimumab was not evaluated for severe and potentially 
lethal forms), won’t make you feel better (no clear results 
on quality of life or steroid sparing), and may have rare but 
life-threatening side effects (long-term evaluation is needed 
to conclude), but, considering that you are not black and that 
your lupus is biologically active, with a monthly infusion, 
it will keep your lupus from worsening for several months 
(negative 76 week results).” Hope? Or false hope?
The modality of administration is also an important issue 
with regards to patient adherence. Indeed, nonsevere patients 
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are mostly managed as outpatients and because they have to 
come to a hospital monthly this factor probably also has a 
negative impact on QoL and/or adherence in some patients. 
However, a Phase II study on belimumab administered sub-
cutaneously is ongoing (Table 2).
A few important issues should be evaluated before the 
initiation of belimumab to SLE patients refractory to SOC. 
First, a significant proportion of so-called refractory SLE 
patients are likely to have insufficient drug exposure due to 
either poor observance or inter-individual variability to drug 
metabolism, the primary source of treatment failure. Thus, 
adherence to treatment needs to be assessed using, among 
other ways, unscheduled measurement of drug blood levels, 
as proposed by Arnaud and colleagues,49 to avoid unnecessary 
therapeutic intensification. Also, physicians could ideally 
enroll patients with persistent nonobservance in a thera-
peutic education program dedicated to SLE, to maximize 
their general adherence to treatment. Finally, due to its good 
tolerance profile and efficacy, there is a consensus for giving 
antimalarials to all SLE patients,14 which was not the case for 
a third of patients in the BLISS trial (Table 4). Conversely, in 
cases of real intolerance or a contraindication to antimalarials, 
belimumab could be an interesting option instead of switch-
ing to long-term immunosuppressive treatments.
Conclusion: belimumab’s  
place in therapy
Despite the need for huge trials and unique trial endpoints to 
demonstrate the drug’s modest efficacy, belimumab could be 
useful in some carefully selected patients, and the approval 
of belimumab for SLE seems to be only the beginning of a 
long path to defining its role in real life.
In the meantime, we can already distinguish different 
patients/situations. First, for patients with severe flare-ups 
(nephritis or CNS), belimumab should not be used because 
there are no data available concerning these patients and 
because the slow onset of belimumab might not be compatible 
with the rapid control needed for a severe flare-up. Secondly, 
for patients with mild flare-ups, if they fulfill the approval 
terms (seropositive in the USA or seropositive with presence 
of anti-DNA and low complement in Europe), belimumab 
might be initiated in patients refractory to SOC. Nevertheless, 
due to the mild effect, especially on steroid sparing and some 
unavoidable reported serious side effects, black patients should 
not receive belimumab until additional data are available and 
only nonblack patients with real refractory disease (mean-
ing with biologically active or high steroid dose, and good 
exposure/adherence to SOC, including ideally antimalarials) 
might be proposed for this new biotherapy. In cases of intol-
erance/contraindication to antimalarials, belimumab could 
also be a useful alternative. Initiation should be monitored 
across a registry, as proposed for other biologics,50 to better 
characterize tolerance profiles in the long term.
Finally, physicians taking care of SLE patients are well 
aware that there is an urgent need to individualize therapy 
in such a heterogeneous disease. Efforts should be made 
to improve identification of patients who might respond to 
anti-BLyS. New tools available to fully assess the immune 
response of SLE patients across time should be evaluated to 
monitor treatment and also to predict drug responders.51,52 
Now that the era of biologics in SLE has come, questions 
about identification of appropriate lupus patients with active 
disease, trial endpoints, and the subgrouping of lupus patients 
remain, and independent efforts are needed to prevent the 
approval of a new biologic that relies on the use of its own 
“tailored” index.11,43
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